Zymeworks (NASDAQ:ZYME) Price Target Raised to $58.00

Zymeworks (NASDAQ:ZYME) had its price objective lifted by Leerink Partners from $52.00 to $58.00 in a report published on Tuesday morning,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

A number of other equities analysts also recently weighed in on the stock. Stifel Nicolaus raised their target price on shares of Zymeworks from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, November 19th. HC Wainwright raised their price objective on Zymeworks from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Wall Street Zen cut Zymeworks from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Citigroup began coverage on Zymeworks in a research note on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Zymeworks presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Zymeworks Stock Performance

ZYME stock opened at $24.80 on Tuesday. The firm has a market cap of $1.83 billion, a P/E ratio of -22.96 and a beta of 1.23. The firm’s fifty day moving average is $23.78 and its 200 day moving average is $21.01. Zymeworks has a 52 week low of $9.03 and a 52 week high of $28.49.

Zymeworks (NASDAQ:ZYME) last issued its earnings results on Monday, March 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Zymeworks had a negative net margin of 76.56% and a negative return on equity of 26.00%. The company had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $21.78 million. During the same quarter in the prior year, the company earned ($0.31) earnings per share. The company’s revenue was down 91.9% compared to the same quarter last year.

Insider Transactions at Zymeworks

In other Zymeworks news, COO Mark Hollywood sold 6,120 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $22.67, for a total value of $138,740.40. Following the transaction, the chief operating officer directly owned 132,913 shares in the company, valued at approximately $3,013,137.71. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kenneth Galbraith sold 54,343 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25.10, for a total value of $1,364,009.30. Following the completion of the transaction, the chief executive officer directly owned 158,286 shares in the company, valued at approximately $3,972,978.60. This represents a 25.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 187,933 shares of company stock worth $4,673,716 in the last ninety days. Insiders own 33.51% of the company’s stock.

Hedge Funds Weigh In On Zymeworks

Several large investors have recently made changes to their positions in ZYME. EcoR1 Capital LLC boosted its position in shares of Zymeworks by 33.1% during the 2nd quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company’s stock valued at $288,278,000 after acquiring an additional 5,710,840 shares during the last quarter. Siren L.L.C. purchased a new stake in Zymeworks during the fourth quarter valued at $44,238,000. Perceptive Advisors LLC lifted its position in Zymeworks by 56.0% during the fourth quarter. Perceptive Advisors LLC now owns 3,261,850 shares of the company’s stock valued at $85,885,000 after purchasing an additional 1,171,187 shares during the last quarter. Rubric Capital Management LP grew its stake in shares of Zymeworks by 22.1% in the 4th quarter. Rubric Capital Management LP now owns 5,750,000 shares of the company’s stock worth $151,398,000 after buying an additional 1,039,449 shares in the last quarter. Finally, Capricorn Fund Managers Ltd purchased a new position in shares of Zymeworks in the 4th quarter worth $26,931,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Lifesci Capital raised several later-quarter and full?year FY2026 EPS estimates (Q2, Q3, Q4 and FY2026 were revised to be materially less negative or positive), signaling improving expectations for Zymeworks’ 2026 profitability outlook. MarketBeat Analyst Note
• Positive Sentiment: Stifel Nicolaus boosted its price target to $47, and Leerink issued a bullish outlook — analyst upgrades and higher targets support upside sentiment and explain earlier intraday gains. Stifel Price Target Leerink Note
• Positive Sentiment: Media noted a short-term positive reaction to analyst upgrades (shares rose on upgrade headlines). Upgrade Reaction
• Neutral Sentiment: Consensus analyst stance remains constructive overall (average recommendation ~“Moderate Buy”), which provides informational support but not immediate fundamental change. Analyst Consensus
• Negative Sentiment: Recent Q4 results were a clear negative catalyst: EPS missed and revenue plunged year?over?year (top-line far below expectations), highlighting the volatility of Zymeworks’ milestone-driven model and near-term execution risk. This underpins profit worries despite longer-term analyst upgrades. FY25 Review / Q4 Analysis
• Negative Sentiment: Lifesci also lowered its Q1 2026 EPS forecast (from a prior positive to a negative), signaling near-term softness that likely offsets some of the enthusiasm from later?year upgrades. MarketBeat Analyst Note

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.